37 completed, 6 terminated, 5 unknown, 2 withdrawn. 38 Phase 2, 12 Phase 1, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 38 | Completed 28, Terminated 4, Unknown 4, Withdrawn 2 |
| Phase 1 | 12 | Completed 9, Unknown 2, Terminated 1 |
| Phase 3 | 8 | Completed 6, Terminated 2 |
Follow Estramustine: new trials by email Literature Review of Estramustine trials Research Report on Estramustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Estracyt® in Metastatic Breast Cancer Estramustine, standard practice - Breast Cancer | Phase 2 | Withdrawn | Centre Hospitalier Universitaire de Besancon | 2017-01-01 | 2019-11-18 | |
| Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer Doxorubicin, Ketoconazole, Docetaxel - Prostatic Neoplasms | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 19 | 2015-11-01 | 2018-11-28 |
| Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer Degarelix, Doxorubicin, Ketoconazole - Prostate Cancer | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 4 | 2015-10-01 | 2018-11-27 |
| Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor. Estramustine, Tamoxifen - Breast Cancer | Phase 2 | Completed | Institut de Cancérologie de Lorraine | 100 | 2011-06-15 | 2020-03-09 |
| Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer Docetaxel + Estramustine + Hydrocortisone, Docetaxel + Prednisone - Prostatic Neoplasms | Phase 3 | Terminated | Sanofi | 54 | 2006-08-01 | 2010-11-30 |
| Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer Docetaxel, Estramustine - Prostate Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 30 | 2004-08-01 | 2011-05-03 |
| Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate docetaxel, estramustine phosphate sodium, thalidomide - Prostate Cancer | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 60 | 2004-03-01 | 2012-03-15 |
| Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment Docetaxel, Estramustine, Casodex - Adenocarcinoma of the Prostate, Prostate Cancer | Phase 2 | Completed | Dana-Farber Cancer Institute | 62 | 2004-03-01 | 2018-06-25 |
| Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer Doxil and Estramustine - Prostate Cancer | Phase 1 / Phase 2 | Terminated | Morton Plant Mease Health Care | 30 | 2003-12-01 | 2006-11-08 |
| Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer docetaxel, estramustine, prednisone - Hormone Resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Completed | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 150 | 2003-12-01 | 2009-10-27 |
| Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer estramustine phosphate sodium, paclitaxel, topotecan hydrochloride - Prostate Cancer | Phase 2 | Withdrawn | Fox Chase Cancer Center | 2003-11-01 | 2013-07-10 | |
| Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer docetaxel, estramustine phosphate sodium, ketoconazole - Prostate Cancer | Phase 3 | Completed | Eastern Cooperative Oncology Group | 2003-10-08 | 2023-06-15 | |
| Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse bicalutamide, Goserelin Acetate, docetaxel - Prostate Cancer | Phase 3 | Completed | UNICANCER | 413 | 2002-11-14 | 2023-01-18 |
| Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy recombinant interferon alfa-2b, docetaxel, estramustine phosphate sodium - Prostate Cancer | Phase 2 | Terminated | University of Medicine and Dentistry of New Jersey | 40 | 2002-11-01 | 2009-12-11 |
| Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy docetaxel, estramustine phosphate sodium, exisulind - Prostate Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 80 | 2002-11-01 | 2016-07-01 |
| Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer bicalutamide, docetaxel, doxorubicin hydrochloride - Prostate Cancer | Phase 3 | Completed | Radiation Therapy Oncology Group | 21 | 2002-10-01 | 2020-10-22 |
| A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer Epirubicin, Estramustine Phosphate, Celecoxib - Prostate Cancer | Phase 2 | Unknown | Department of Veterans Affairs, New Jersey | 28 | 2002-07-01 | 2005-09-22 |
| Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium - Prostate Cancer | Phase 3 | Terminated | M.D. Anderson Cancer Center | 265 | 2002-04-01 | 2016-03-22 |
| Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate Zoledronic acid, Estramustine, Docetaxel - Hormone-Refractory Prostate Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 28 | 2002-04-01 | 2015-01-22 |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer bicalutamide, estramustine, etoposide - Prostate Cancer | Phase 2 | Completed | SWOG Cancer Research Network | 41 | 2001-12-01 | 2013-07-16 |
Showing 20 of 50. Sign in to see all of them.
Prostatic Neoplasms (43) · Breast Neoplasms (3) · Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Neoplasm Metastasis (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Carcinoma, Renal Cell (1) · Fibrosarcoma (1)
M.D. Anderson Cancer Center (5) · Alliance for Clinical Trials in Oncology (3) · Eastern Cooperative Oncology Group (3) · Herbert Irving Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · University of Michigan Rogel Cancer Center (3) · Dana-Farber Cancer Institute (2) · Fox Chase Cancer Center (2) · NYU Langone Health (2) · Radiation Therapy Oncology Group (2) · SCRI Development Innovations, LLC (2) · SWOG Cancer Research Network (2) · The University of Texas Health Science Center, Houston (2) · University of New Mexico (2) · Beth Israel Deaconess Medical Center (1)
United States (43) · France (3) · Canada (2) · Puerto Rico (2) · Australia (1) · Belgium (1) · Luxembourg (1) · Peru (1) · South Africa (1) · Spain (1)
David C. Smith, MD (4) · Daniel P. Petrylak, MD (3) · William K. Kelly, DO (3) · Gary R. Hudes, MD (2) · Gregory P. Swanson, MD (2) · Randall E. Millikan, MD, PhD (2) · Robert S. DiPaola, MD (2) · William Oh, MD (2) · Abraham Chachoua, MD (1) · Amy D. Tiersten, MD (1) · Anthony A. Meluch, MD (1) · Anthony Y. Smith, MD (1) · Arif Hussain, MD (1) · Avi S. Retter, MD (1) · Basil Kasimis, MD (1)
PMID 10604271, PMID 12610188, PMID 14504052, PMID 14669278, PMID 14747052, PMID 15470214, PMID 15671557, PMID 15735119, PMID 16258090, PMID 16622120, PMID 16782921, PMID 18824434, PMID 18989865, PMID 18990504, PMID 19029421, PMID 19130298, PMID 22119204, PMID 26028518, PMID 26209502, PMID 28586789, PMID 36596347
U10CA031946 (4), P30CA016672 (3), U10CA032102 (2), 2009 (1), P30CA006927 (1), P30CA016087 (1), P30CA072720 (1), U10CA045809 (1)